Neuropep Therapeutics

The First Company
Addressing the
True Cause
of Alzheimer's.

Pioneering a paradigm shift in treating Alzheimer's and Parkinson's through neuropeptide preservation and replacement.

153MProjected global Alzheimer's patients by 2050
52.5%Reduction in AD incidence in real-world patient data with a drug containing our oral monotherapy candidate
$1.3TProjected annual US dementia cost by 2050
The Science

A Loss of Function,
Not a Gain of Toxicity

Even drugs that successfully reduced plaques by nearly 70% showed no cognitive improvement — and direct amyloid blocking drugs actually accelerated decline.

The breakthrough insight: Alzheimer's and Parkinson's are driven by neuropeptide depletion, not accumulation. When soluble neuropeptide levels fall below a critical threshold, synapses fail and cognition collapses.

We restore what the brain needs.

Neuropep Therapeutics focuses on restoring synaptic function and recovering memory formation via two complementary approaches: protection of endogenous peptides in the CSF, and replacement via stable peptide analogues.

Neuropep laboratory research
The Depletion Model of Alzheimer's Disease
The Depletion Model of Alzheimer's Disease
"

The brain isn't poisoned.
It's starving.

— The founding insight behind Neuropep Therapeutics
Evidence Foundation
Clinical Trial DataTrials targeting the plaque hypothesis have decisively failed. Anti-amyloid drugs achieving 70% plaque clearance demonstrated no statistically significant cognitive improvement across multiple Phase III trials, 2020–2023.
Real-World Patient Data52.5% reduction in Alzheimer's incidence observed in real-world patients treated with an oral medication containing our neuropeptide protective monotherapy candidate, consistent across independent cohorts.
Biomarker EvidenceExtensive clinical data across 210 studies and 24,000 subjects demonstrates that healthy individuals maintain significantly higher levels of our selected neuropeptide, with concentrations nearly double those found in patients with Alzheimer's disease.
Mechanistic BasisNeuropeptides previously classified as pathogenic are now evidenced to serve essential synaptic and memory functions when maintained at physiological levels — with demonstrated restoration of function through therapeutic repletion.
Our Position

Insight-Driven.
Evidence-Backed.

The Paradigm Problem

Decades of research targeting protein aggregation in neurodegenerative diseases have yielded limited clinical success. We believe this reflects a fundamental misunderstanding of disease mechanism.

Recent evidence suggests that certain neuropeptides previously thought to be pathogenic may actually serve critical physiological functions. Their depletion, rather than their accumulation, may drive disease progression.

Our Thesis

Neuropep Therapeutics is developing a dual approach: protecting endogenous neuropeptides from degradation and developing novel peptide replacement therapeutics.

We're combining insights from evolutionary biology, clinical trial data, and preclinical research to address what we believe is the underlying pathophysiology of Alzheimer's and related conditions.

The first therapy to repair the most well evidenced human biomarker for Alzheimer's disease
Therapeutic Strategy

Two-Track Platform

Addressing neurodegeneration at multiple stages — from prevention to potential reversal.

Track 01 — Protect

Neuropeptide Preservation

Novel Oral Monotherapy · De-Risked Pathway

A novel oral monotherapy formulation — first to market for this specific approach — protecting endogenous neuropeptides from degradation. Derived from an FDA-approved therapeutic with established safety profile, our proprietary formulation represents new intellectual property with a de-risked development pathway.

Track 02 — Replace

Peptide Replacement

Second-Generation Analogues · Potentially Curative

Second-generation non-aggregating peptide analogues with novel structural modifications, enhanced brain penetration, and optimized stability. Neuropep Therapeutics is racing to become the first company to deliver a curative neuropeptide replacement therapy — safe, non-aggregating analogues that directly restore the synaptic function lost in Alzheimer's and Parkinson's disease.

Neuropep Therapeutics — Protect and Replace Neuropeptides
01Protect
Preserve endogenous neuropeptides from degradation with a novel oral monotherapy
02Replace
Second-generation non-aggregating peptide analogues with enhanced brain penetration
03Restore
The first potentially curative therapy targeting Alzheimer's most well-evidenced mechanism
Leadership

The Founders

Kariem Ezzat
Kariem Ezzat
Co-Founder & CEO
  • 15+ years at Oxford, Karolinska & Stockholm University
  • PhD in Neurochemistry & Molecular Neurobiology
  • Numerous high-impact publications on aggregation biophysics and neurodegeneration
Tom Baxter
Tom Baxter
Co-Founder & CFO
  • CFO-level expertise across SaMD, fintech, and life sciences — 20+ years
  • Led startups from Angel Investment through PE-backed Series D
  • Deep expertise in M&A, debt financing, and governance
Matthew David
Matthew David
Co-Founder & CBDO
  • Dual training as mathematician / physician
  • Former Google Networks quantitative analyst
  • MD, TAMU COM + Baylor Dallas ('26), Editorial Board: World Journal of Surgery
Contact

Partner With Us to Change the Future of Alzheimer's

For investment inquiries and partnership opportunities. We welcome conversations with accredited investors at all stages.

Breakthrough preventative therapy candidate — safety validated
Racing to be first with curative neuropeptide replacement therapy — safe, non-aggregating peptide analogues
52.5% reduction in AD incidence in real-world patient data with a drug containing our oral monotherapy candidate
Experimentally & clinically validated dual-mechanism platform